Novel Psychopharmacologic Interventions in Oncology
Psychiatrists, psychologists, psychiatric nurses, social workers, and healthcare professionals in related disciplines need to receive regular updates on advances in neuroscience, psychiatric research, psychotherapy, and the evolving best practices for evaluating, diagnosing, and treating psychiatric disorders. The series aims to improve clinical practice through critical appraisal of psychiatric research, the use of evidence-based treatment approaches, and the integration of multiple treatment modalities to enhance the quality of psychiatric care and improve patient outcomes.
Physicians, fellows, residents, nurses, and other health professionals.
At the conclusion of the session, the participants should be able to:
Recognize that patients with cancer are using psychopharmacologic drugs such as cannabinoids/cannabis, ketamine, MDMA (3,4-methylenedioxymethamphetamine), and psilocybin to manage their psychological and physical symptoms.
List the most common reasons why patients with cancer use cannabis.
Outline the U.S. Food and Drug Administration indications for cannabis use in patients with cancer.
Describe two currently researched indications for psilocybin-assisted psychotherapy.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Social Work: Baylor College of Medicine, Division of Continuing Professional Development (License Number 7270) is an approved continuing education provider for Social Workers through the Texas State Board of Social Worker Examiners. This activity has been approved for 0.75 continuing education unit.
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Participation
- 0.75 Social Work